Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 6,490 shares at $60.00 ($389K) on 2017-11-29, disclosed to the SEC on 2017-11-30.
Seasonal sale ($389k) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in November in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |